Dee Chaudhary
Director, Consulting
With more than 25 years in life sciences and a passion for patients, Dee Chaudhary is a Director with Clarivate’s Commercial Strategy Consulting practice. Her work in consulting, and within the biopharmaceutical industry has primarily focused on HUB/patient services, launch readiness, CMS policy impact, customer experience and market access strategy in the hematology and oncology space.
Dee has extensive professional experience with 340B pricing, reimbursement strategy, product positioning and value propositions for oral and infusible agents. She has led HUB migrations, benchmarking engagements, customer satisfaction projects, omni-channel projects, product differentiation, pricing and positioning efforts, and payer landscape analysis. Furthermore, Dee has an in-depth understanding of the hematology and oncology market landscape, targeted and cellular therapies, and has a strong interest and experience in other therapeutic areas including cardiology, neuroscience, med tech immunotherapy, and using technology to advance health and access. She has been invited to presented at Asembia, ISPOR and other clinical meetings, and has authored multiple trainings and white papers.
Prior to joining Clarivate, Dee held a variety roles at small and large biopharmaceutical organizations and consulting firms, including National Director of Market Access, Reimbursement and Trade, Senior Director of Customer Experience, and Assistant Director of Reimbursement Consulting. Dee holds a BA from Gustavus Adolphus College in History, and an MBA in Healthcare Administration.
Latest news
Clarivate Presents Cortellis Regulatory AI Assistant to Cut Through Complexity in Safety and Compliance
Powered by agentic AI, new features help regulatory teams improve accuracy and enable faster, more confident decisions across the product lifecycle London, U.K. — December 4, 2025 — Clarivate Plc…
Clarivate and the Chinese Academy of Sciences Release the 2025 Research Fronts Report
Annual report identifies 110 hot and 18 emerging Research Fronts London, U.K. December 3, 2025. Clarivate Plc (NYSE: CLVT), a leading global provider of transformative intelligence, and the Chinese Academy…
Clarivate Reveals Global Shifts in Research Collaboration
New report explores multilateral partnerships, Mainland China’s rising influence, and strategic challenges for the U.S. London, U.K. December 2, 2025: Clarivate Plc (NYSE:CLVT), a leading global provider of transformative intelligence,…